Abstract
Background: Cytotherapy products can be described as “living drugs”. Cytotherapy is the swiftest growing fields in the treatment of cancer, heart diseases, aging population and neuromuscular ailments. Biomimetic approaches are processes developed by humans such as devices, substances, or systems that mimic nature or natural processes.
Objective and Method: It aims at developing a base for personalized medicine with allogeneic, autologous and xenogenic therapies where cells are modified for target selection. Such drug delivery methods appear to be complex and challenging. Literature for approximately past two decades was collected and reviewed for the present article.
Results and Conclusion: The opportunities and challenges in cytotherapy have been classified, discussed and demystified. Various process inputs, materials and process conditions required in bioprocessing and preservation have been discussed at length. The review also focuses on the regulatory requirements in India, Europe and U.S.
Keywords: Cytotherapy, bioprocessing, regulatory requirements, biomimetic, nanomedicine, allogeneic.
Graphical Abstract
[1]
Muller B, Van de Voorde M. Nanoscience and Nanotechnology for Human Health. John Wiley & Sons 2017.
[2]
Borm PJ, Kreyling W. Toxicological hazards of inhaled nanoparticles-potential implications for drug delivery. J Nanosci Nanotechnol 2004; 4: 521-31.
[3]
Oberdorster G, Oberdorster E, Oberdorster J. Nanotoxicology: an emerging discipline evolving from studies of ultrafine particles. Environ Health Perspect 2005; 823-39.
[4]
Granum B, Løvik M. The effect of particles on allergic immune responses. Toxicol Sci 2002; 65: 7-17.
[5]
The new age of regenerative medicine market research. Frost Sullivan 2015. http://www.frost.com/sublib/display-report.do?id=9AB9-00-3D-00-00&bdata=aHR0cDovL3d3dy5mcm9zdC5jb20vcHJvZC9zZXJ2bGV0L3NlZ21lbnQtY nJvY2h1cmUucGFnP2lkPTlBQjktMDAtM0QtMDAtMDB AfkBCYWNrQH5AMTU0NjUwNTg0NzU4MQ%3D%3D (Accessed on September 19, 2017).
[6]
Regenerative medicine market by technology, material and application - Global opportunity analysis and industry forecasts, 2017 - 2023. https://www.alliedmarketresearch.com/ get-discount/391 (Accessed on September 10, 2017).
[7]
Choi MR, Stanton-Maxey KJ, Stanley JK, et al. A cellular Trojan Horse for delivery of therapeutic nanoparticles into tumors. Nano Lett 2007; 7: 3759-65.
[8]
8- Seo SH, Kim KS, Park SH, et al. The effects of mesenchymal stem cells injected via different routes on modified IL-12-mediated antitumor activity. Gene Ther 2011; 18: 488-95.
[9]
Jain A, Bansal R. Applications of regenerative medicine in organ transplantation. J Pharm Bioallied Sci 2015; 7: 188-94.
[11]
Yoo JW, Irvine DJ, Discher DE, Mitragotri S. Bio-inspired, bioengineered and biomimetic drug delivery carriers. Nat Rev Drug Discov 2011; 10: 521-35.
[12]
Frankel TL, Burns WR, Peng PD, et al. Both CD4 and CD8 T cells mediate equally effective in vivo tumor treatment when engineered with a highly avid TCR targeting tyrosinase. J Immunol 2010; 184: 5988-98.
[13]
Manjunath SR, Ramanan G, Dedeepiya VD, et al. Autologous immune enhancement therapy in recurrent ovarian cancer with metastases: a case report. Case Rep Oncol 2012; 5: 114-8.
[15]
Chandramohan V, Mitchell DA, Johnson LA, Sampson JH, Bigner DD. Antibody, T-cell and dendritic cell immunotherapy for malignant brain tumors. Future Oncol 2013; 9: 977-90.
[16]
Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009; 10: 459-66.
[17]
Autologous Immune Enhancement Therapy. Immunotherapy for cancer in Japan, cancer oncology malignancy using lymphocytes activation http: //www.immunotreatment.org/ (Accessed on September 20, 2017).
[18]
Denise G. Cell Therapy Shows Promise for Acute Type of Leukemia The New York Times 2013 March 20: Available from:.https://www.nytimes.com/2013/03/21/health/altered-t-cell-therapy-shows-promise-for-acute-leukemia.html
[19]
Gutierrez Millan C, Colino Gandarillas CI, Sayalero Marinero ML, Lanao JM. Cell-based drug-delivery platforms. Ther Deliv 2012; 3: 25-41.
[20]
Ahrlund-Richter L, De Luca M, Marshak DR, Munsie M, Veiga A, Rao M. Isolation and production of cells suitable for human therapy: challenges ahead. Cell Stem Cell 2009; 4: 20-6.
[21]
Challener CA. Cell and Gene Therapies Face Manufacturing Challenges. Biopharm Int 2017; 30: 20-5.
[22]
Dodson BP, Levine AD. Challenges in the translation and commercialization of cell therapies. BMC Biotechnol 2015; 15: 70.
[23]
Single use bioreactor market by product, application amp; technology - 2021 Markets and Markets 2016. Available from: https://www.marketsandmarkets.com/Market-Reports/single-use-bioreactor-market-49113750.html
[25]
European medicines agency - Find medicine - Provenge https://www.ema.europa.eu/en/medicines/human/EPAR/provenge (Accessed on July 16, 2017).
[26]
Hu R, George DJ, Zhang T. What is the role of sipuleucel-T in the treatment of patients with advanced prostate cancer? An update on the evidence. Ther Adv Urol 2016; 8(4): 272-8.
[27]
Tavassoli M, Crosby WH. Transplantation of marrow to extramedullary sites. Science 1968; 161: 54-6.
[28]
Pharmacopeia US. Cell and gene therapy products-Manufacturing overview. US Pharmacopeial Convention Inc: Rockville, MD 2006.
[29]
Song WK, Park KM, Kim HJ, et al. Treatment of macular degeneration using embryonic stem cell-derived retinal pigment epithelium: preliminary results in Asian patients. Stem Cell Reports 2015; 4: 860-72.
[30]
Idelson M, Alper-Pinus R, Obolensky A, Banin E, Reubinoff B. Stem cell-derived retin retinal pigment epithelial cells. US Patent 2011/0027333 A1 February 3, 2011.
[31]
Reubinoff B, Bar-Giora M. Undifferentiated stem cell culture systems. US Patent 2007/0212777 A1, September 13, 2007.
[32]
Reubinoff BE, Yachimovich-cohen N, Matzrafi L. Methods of selecting retinal pigmented epithelial cells Patent 2013/114360 Al, August 8, 2013.
[33]
Coopman K, Medcalf N. From production to patient: challenges and approaches for delivering cell therapies. In: Stem cell research community (eds) StemBook 2014.
[34]
Bader P, Kuçi Z, Bakhtiar S, et al. Effective treatment of steroid and therapy-refractory acute graft-versus-host disease with a novel mesenchymal stromal cell product (MSC-FFM). Bone Marrow Transplant 2018; 53(7): 852-62.
[35]
Miyamura K. Insurance approval of mesenchymal stem cell for acute GVHD in Japan: need of follow up for some remaining concerns. Int J Hematol 2016; 103(2): 155-64.
[36]
Ayre A, Nambiar S, Marathe K, Nair D. Headway into the insights and applications of xenogenic cell therapy. Innov J Med Health Sci 2016; 6(2): 41-4.
[37]
Yoo D, Giulivi A. Xenotransplantation and the potential risk of xenogeneic transmission of porcine viruses. Can J Vet Res 2000; 64: 193-203.
[38]
Cardona K, Milas Z, Strobert E, et al. Engraftment of adult porcine islet xenografts in diabetic nonhuman primates through targeting of costimulation pathways. Am J Transplant 2007; 7: 2260-8.
[39]
Dufrane D, Gianello P. Pig islets for clinical islet xenotransplantation. Curr Opin Nephrol Hypertens 2009; 18: 495-500.
[40]
Pitkin Z. New Phase of Growth for Xenogeneic-Based Bioartificial Organs. Int J Mol Sci 2016; 17(9): E1593.
[42]
Williams DJ, Thomas RJ, Hourd PC, et al. Precision manufacturing for clinical-quality regenerative medicines. Philos Trans A Math Phys. Eng Sci 2012; 370: 3924-49.
[43]
Wang YK, Chen CS. Cell adhesion and mechanical stimulation in the regulation of mesenchymal stem cell differentiation. J Cell Mol Med 2013; 17: 823-32.
[44]
Bravery CA, Carmen J, Fong T, et al. Potency assay development for cellular therapy products: an ISCT review of the requirements and experiences in the industry. Cytotherapy 2013; 15: 9-19.
[45]
Golab K, Leveson-Gower D, Wang XJ, et al. Challenges in cryopreservation of regulatory T cells (Tregs) for clinical therapeutic applications. Int Immunopharmacol 2013; 16(3): 371-5.
[46]
Hunt CJ. Cryopreservation of human stem cells for clinical application: a review. Transfus Med Hemother 2011; 38: 107-23.
[47]
47. David F, Andy L, Gautam B. Directly injectable formulations which provide enhanced cryoprotection of cell products. US Patent 2004/0121300 A1, 2004.
[48]
Koch E, Larak M, Ellendorff F. Comparative studies on in vitro reactivity of fresh and cryopreserved pig lymphocytes. Cryobiology 1991; 28: 405-12.
[49]
Shu Z, Heimfeld S, Gao D. Hematopoietic SCT with cryopreserved grafts: adverse reactions after transplantation and cryoprotectant removal before infusion. Bone Marrow Transplant 2014; 49: 469-76.
[50]
Cox MA, Kastrup J, Hrubiško M. Historical perspectives and the future of adverse reactions associated with haemopoietic stem cells cryopreserved with dimethyl sulfoxide. Cell Tissue Bank 2012; 13: 203-15.
[51]
Mathew AJ, Van Buskirk RG, Baust JG. Improved hypothermic preservation of human renal cells through suppression of both apoptosis and necrosis. Cell Preserv Technol 2002; 1: 239-53.
[52]
Wise H, Abel PW, Cawkill D. Use of reduced temperature cell pausing to enhance flexibility of cell-based assays. J Biomol Screen 2009; 14: 716-22.
[53]
Roobol A, Carden MJ, Newsam RJ, Smales CM. Biochemical insights into the mechanisms central to the response of mammalian cells to cold stress and subsequent rewarming. FEBS J 2009; 276: 286-302.
[54]
ChondroCelect http: //www.ema.europa.eu/ema/index.jsp? curl=pages/medicines/human/medicines/000878/human_med_000698.jspmid=WC0b01ac058001d124 (Accessed on January 12, 2017).
[55]
Calmels B, Houze P, Hengesse JC, Ducrot T, Malenfant C, Chabannon C. Preclinical evaluation of an automated closed fluid management device: CytomateTM, for washing out DMSO from hematopoietic stem cell grafts after thawing. Bone Marrow Transplant 2003; 31: 823-8.
[56]
Kebriaei P, Isola L, Bahceci E, et al. Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft-versus-host disease. Biol Blood Marrow Transplant 2009; 15: 804-11.
[57]
57. Geigert J. The challenge of CMC regulatory compliance for biopharmaceuticals and other biologics. Springer: 2013.
[58]
ICH Q6B Note for Guidance on Specifications: Test Procedures and Acceptance Criteria for Biotechnological / Biological Products (CPMP/ICH/365/96)..
[59]
Guideline on human cell-based medicinal products https: //www.ema.europa.eu/documents/scientific-guideline/ guideline-human-cell-based-medicinal-products_en.pdf (Accessed on July 5, 2017).
[60]
Regulation (EC) NO 1394/2007 of the European Parliament and of the council of 13 november 2007 on advanced therapy medicinal products and amending directive 2001/83/EC and regulation (EC) NO 726/2004. Official J European Union 2007.
[61]
FDA U. Food and Drug Administration. CFR-Code of Federal Regulations Title 21. Food and Drug. 2013.
[62]
FDA U. Guidance for industry: environmental assessment of human drug and biologics applications. Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER), editor. 1998.
[63]
Ganguly N, Geeta J, Roli M, Valiathan M. Ethical Guidelines for Biomedical Research on Human Participants. New Delhi: ICMR 2006.
[64]
ICMR-DBT Guidelines for Stem Cell Research. Indian Council of Medical Research 2017. Available from:
http:// www.dbtindia.nic.in/wp-content/uploads/National_Guidelines_ StemCellResearch-2017.pdf
[65]
Central Drugs Standard Control Organization Guidance for industry 2008 Available from: http://www.cdsco.nic.in/ writereaddata/CDSCO-GuidanceForIndustry.pdf
Article Metrics
97
4
1